ContraVir Pharmaceuticals Company Profile (NASDAQ:CTRV)

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals logoContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company's CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company's CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company's FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTRV
  • CUSIP: N/A
  • Web: www.contravir.com
Capitalization:
  • Market Cap: $37.78 million
  • Outstanding Shares: 63,707,000
Average Prices:
  • 50 Day Moving Avg: $0.53
  • 200 Day Moving Avg: $0.85
  • 52 Week Range: $0.45 - $2.65
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.02) per share
  • Price / Book: -22.51
Profitability:
  • EBIDTA: ($21,360,000.00)
  • Return on Assets: -168.58%
Debt:
  • Current Ratio: 2.65%
  • Quick Ratio: 2.65%
Misc:
  • Average Volume: 661,198 shs.
  • Beta: 2.37
  • Short Ratio: 11.36
 

Frequently Asked Questions for ContraVir Pharmaceuticals (NASDAQ:CTRV)

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) announced its quarterly earnings data on Friday, May, 13th. The company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.09. View ContraVir Pharmaceuticals' Earnings History.

When will ContraVir Pharmaceuticals make its next earnings announcement?

ContraVir Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, September, 27th 2017. View Earnings Estimates for ContraVir Pharmaceuticals.

Where is ContraVir Pharmaceuticals' stock going? Where will ContraVir Pharmaceuticals' stock price be in 2017?

2 analysts have issued 1 year price targets for ContraVir Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect ContraVir Pharmaceuticals' share price to reach $4.00 in the next twelve months. View Analyst Ratings for ContraVir Pharmaceuticals.

Who are some of ContraVir Pharmaceuticals' key competitors?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Chairman of the Board
  • James E. Sapirstein, Chief Executive Officer, Director
  • John T. Cavan, Chief Financial Officer
  • Robert T. Foster Ph.D., Chief Scientific Officer
  • Theresa Matkovits, Senior Vice President—Drug Development
  • John Z. Sullivan-Bolyai, Chief Medical Officer
  • Tamar D. Howson, Director
  • Thomas H. Adams Jr. Ph.D., Independent Director
  • Timothy Block, Independent Director
  • John P. Brancaccio CPA, Independent Director

Who owns ContraVir Pharmaceuticals stock?

ContraVir Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.79%), HighTower Advisors LLC (1.64%) and JPMorgan Chase & Co. (0.31%). Company insiders that own ContraVir Pharmaceuticals stock include James Sapirstein and John T Cavan. View Institutional Ownership Trends for ContraVir Pharmaceuticals.

Who bought ContraVir Pharmaceuticals stock? Who is buying ContraVir Pharmaceuticals stock?

ContraVir Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought ContraVir Pharmaceuticals stock in the last two years include James Sapirstein and John T Cavan. View Insider Buying and Selling for ContraVir Pharmaceuticals.

How do I buy ContraVir Pharmaceuticals stock?

Shares of ContraVir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of ContraVir Pharmaceuticals stock can currently be purchased for approximately $0.50.


MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ContraVir Pharmaceuticals (NASDAQ:CTRV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (707.75% upside)

Analysts' Ratings History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017Maxim GroupReiterated RatingBuy$4.00LowView Rating Details
4/21/2017Noble FinancialReiterated RatingBuyHighView Rating Details
6/1/2016ING GroupInitiated CoveragePositiveN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Earnings by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Earnings History by Quarter for ContraVir Pharmaceuticals (NASDAQ CTRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/27/2017        
5/13/2016Q3($0.23)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Next Year EPS Consensus Estimate: $-0.41 EPS

Dividends

Dividend History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 10.27%
Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Institutional Ownership by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017John T CavanCFOBuy20,000$0.65$13,000.00View SEC Filing  
2/18/2016James SapirsteinCEOBuy10,000$1.00$10,000.00View SEC Filing  
11/23/2015James SapirsteinCEOBuy2,500$1.64$4,100.00View SEC Filing  
3/4/2014John P BrancaccioDirectorBuy4,393$1.49$6,545.57View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Latest Headlines for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Source:
DateHeadline
thestreet.com logoAchillion Shares Are Plunging on Termination of Hepatitis C Pact - TheStreet.com
www.thestreet.com - September 12 at 6:20 PM
globenewswire.com logoContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL™) in the United States - GlobeNewswire (press release)
globenewswire.com - September 12 at 6:20 PM
streetinsider.com logoContraVir Pharma (CTRV) Reports Acceptance of Clinical Trial Application in the UK, - StreetInsider.com
www.streetinsider.com - September 7 at 3:40 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom
finance.yahoo.com - September 6 at 5:37 PM
globenewswire.com logoContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 12:14 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
finance.yahoo.com - September 5 at 7:11 PM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - August 24 at 3:22 PM
globenewswire.com logoContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program - GlobeNewswire (press release)
globenewswire.com - August 22 at 11:14 PM
streetinsider.com logoContraVir Pharma (CTRV) Granted U.S. Patent for Expansion of Cyclophilin Inhibitor Program
www.streetinsider.com - August 21 at 5:21 PM
americanbankingnews.com logoZacks: Analysts Expect ContraVir Pharmaceuticals Inc (CTRV) to Announce -$0.09 EPS
www.americanbankingnews.com - August 16 at 8:32 PM
nasdaq.com logoContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017
www.nasdaq.com - August 9 at 3:24 AM
globenewswire.com logoContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017 - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:22 PM
finance.yahoo.com logoContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017
finance.yahoo.com - August 8 at 5:22 PM
nasdaq.com logoContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017 - Nasdaq
www.nasdaq.com - August 4 at 5:53 PM
finance.yahoo.com logoContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017
finance.yahoo.com - August 3 at 7:00 PM
americanbankingnews.com logo Analysts Expect ContraVir Pharmaceuticals Inc (CTRV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - July 5 at 12:34 PM
americanbankingnews.com logoInsider Buying: ContraVir Pharmaceuticals Inc (CTRV) CFO Acquires 20,000 Shares of Stock
www.americanbankingnews.com - June 22 at 10:56 AM
finance.yahoo.com logoContraVir Pharmaceuticals to Present at 2017 BIO International Convention
finance.yahoo.com - June 13 at 12:25 PM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 9 at 10:22 AM
finance.yahoo.com logoContraVir Pharmaceuticals to Present at 2017 Marcum MicroCap Conference
finance.yahoo.com - June 8 at 5:37 PM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Short Interest Update
www.americanbankingnews.com - May 28 at 7:14 AM
americanbankingnews.com logoZacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - May 15 at 10:00 AM
streetinsider.com logoContraVir Pharma (CTRV) to Advance Second-Generation Formulation of TXL for Treatment of HBV - StreetInsider.com
www.streetinsider.com - May 6 at 7:58 AM
finance.yahoo.com logoContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL™) for Treatment of Hepatitis B Virus (HBV)
finance.yahoo.com - May 4 at 7:35 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
finance.yahoo.com - May 2 at 7:34 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receives Daily Coverage Optimism Rating of -0.10
www.americanbankingnews.com - May 2 at 12:56 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:26 AM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 25 at 7:26 PM
nasdaq.com logoMid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat Results
www.nasdaq.com - April 25 at 4:20 PM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - April 25 at 11:58 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - April 24 at 4:27 PM
americanbankingnews.com logoZacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 24 at 12:45 PM
streetinsider.com logoContraVir Pharma (CTRV) Presents Data on Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) & CRV431
www.streetinsider.com - April 24 at 9:15 AM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Rating Reiterated by Noble Financial
www.americanbankingnews.com - April 22 at 6:32 PM
finance.yahoo.com logoData Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431
finance.yahoo.com - April 22 at 4:23 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Given Media Sentiment Rating of 0.41
www.americanbankingnews.com - April 21 at 2:18 PM
finance.yahoo.com logoOral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients
finance.yahoo.com - April 20 at 4:43 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Earns Daily Media Impact Rating of 0.56
www.americanbankingnews.com - April 18 at 9:35 AM
americanbankingnews.com logoMaxim Group Analysts Give ContraVir Pharmaceuticals Inc (CTRV) a $4.00 Price Target
www.americanbankingnews.com - April 17 at 10:50 AM
americanbankingnews.com logoMaxim Group Reiterates "$4.00" Price Target for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - April 14 at 3:34 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 14 at 9:46 AM
finance.yahoo.com logoContraVir to Highlight New Data at EASL The International Liver Congress™ 2017 in Amsterdam, The Netherlands
finance.yahoo.com - April 11 at 1:00 PM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 8 at 8:04 AM
americanbankingnews.com logoMaxim Group Reaffirms Buy Rating for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - April 4 at 1:23 PM
nasdaq.com logoContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)
www.nasdaq.com - April 4 at 8:49 AM
finance.yahoo.com logoCONTRAVIR PHARMACEUTICALS, INC. Financials
finance.yahoo.com - February 18 at 4:22 PM
biz.yahoo.com logoCONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 14 at 8:46 PM
finance.yahoo.com logoContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL™) for Treating Hepatitis B
finance.yahoo.com - February 14 at 3:46 PM
prnewswire.com logoContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 7 at 10:44 PM
finance.yahoo.com logoContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 5:41 PM

Social

Chart

ContraVir Pharmaceuticals (CTRV) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff